Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026
Sunday, May 31, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The Phase 2 TeLuRide-005 trial evaluates the efficacy and safety of EIK1001, a TLR 7/8 dual agonist, when added to standard first-line therapy for Stage 4 Non-Small Cell Lung Cancer. The results were presented at ASCO 2026, highlighting promising data that could impact treatment protocols.
Price reaction · baseline $10.84 (2026-05-29 close) · 1 other EIKN headline(s) in the window, move may be shared
day 0 close · peak
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
The trial presents new data on EIK1001's efficacy.
Cytokine profiling may enhance understanding of treatment effects.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Minimal dilution risk
Lead asset
EIK1001
Phase 2 · NSCLC
Full Press Release Details
05/31/2026
Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026
Share
Share on LinkedIn
Frequently Asked Questions
What is the focus of the TeLuRide-005 trial?
The trial focuses on the efficacy and safety of EIK1001 in Stage 4 Non-Small Cell Lung Cancer.
What type of agonist is EIK1001?
EIK1001 is a toll-like receptor (TLR) 7/8 dual agonist.
Where were the results of the trial presented?
The results were presented at ASCO 2026.
What therapy is EIK1001 added to in the trial?
EIK1001 is added to standard of care first-line therapy.